Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Oby Sogbetun Medical Monitor, MD
Precision BioSciences, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Beaujon
Clichy, France, France
Recruiting
- Queen Mary Hospital, the University of Hong Kong
Hong Kong, Hong Kong, Hong Kong
Recruiting
- Ics Arensia Exploratory Medicine Srl
Chisinau, Moldova
Recruiting
- New Zealand Clinical Research
Auckland, New Zealand
Recruiting
- Arensia Exploratory Medicine
Bucharest, Romania, Romania
Recruiting - Arensia Exploratory Medicine in Collaboration With County Clinical Emergency Hospital
Cluj-Napoca, Romania, Romania
Recruiting
- Massachusetts General Hospital/harvard University
Boston, Massachusetts, United States
Raymond T Chung, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Nov 2024
- Primary completion
- 31 Dec 2026
- Completion
- 30 Jun 2027
- Last update posted
- 14 Aug 2026
- Registered enrollment
- 45
- Registry id
- NCT06680232
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.